Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


Publication year:
All
11 - 13 out of 13Page size: 10
Sort by: Title
  1. Published

    Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer

    Schneeweiss, A., Park-Simon, T. W., Albanell, J., Lassen, U., Cortés, J., Dieras, V., May, M., Schindler, C., Marmé, F., Cejalvo, J. M., Martinez-Garcia, M., Gonzalez, I., Lopez-Martin, J., Welt, A., Levy, C., Joly, F., Michielin, F., Jacob, W., Adessi, C., Moisan, A. & 7 others, Meneses-Lorente, G., Racek, T., James, I., Ceppi, M., Hasmann, M., Weisser, M. & Cervantes, A., 2018, In: Investigational New Drugs. 36, 5, p. 848-859 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    TRK Inhibition: A New Tumor-Agnostic Treatment Strategy

    Kummar, S. & Lassen, Ulrik Niels, 2018, In: Targeted Oncology. 13, 5, p. 545-556

    Research output: Contribution to journal › Review › Research › peer-review

  3. Published

    VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance

    Michaelsen, Signe Regner, Staberg, M., Pedersen, H., Jensen, K. E., Majewski, W., Broholm, H., Nedergaard, M. K., Meulengracht, C., Urup, T., Villingshøj, M., Lukacova, S., Skjøth-Rasmussen, J., Brennum, J., Kjær, Andreas, Lassen, Ulrik Niels, Stockhausen, M., Poulsen, H. S. & Hamerlik, P., 2018, In: Neuro-Oncology. 20, 11, p. 1462-1474

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1 2 Next

ID: 4952653